1 asset in Ectomesenchymoma

Therapeutic assets addressing Ectomesenchymoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- Ectomesenchymoma	National Cancer Institute (NCI)	P2	CCC (53)